Tvardi Therapeutics, Inc. (TVRD)
| Market Cap | 14.27M -77.2% |
| Revenue (ttm) | n/a |
| Net Income | -26.06M |
| EPS | -2.77 |
| Shares Out | 13.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 94,575 |
| Open | 1.030 |
| Previous Close | 1.000 |
| Day's Range | 1.000 - 1.070 |
| 52-Week Range | 0.930 - 7.230 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 9.25 (+764.49%) |
| Est. Earnings | Nov 12, 2026 |
About TVRD
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for TVRD stock is "Buy." The 12-month stock price target is $9.25, which is an increase of 764.49% from the latest price.
News
Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference
HOUSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral sm...
Tvardi announces publication of preclinical data on STAT3 inhibitor
Tvardi Therapeutics (TVRD) announced the publication of preclinical data evaluating Tvardi’s STAT3 inhibitor in the International Journal of Molecular Sciences. The publication provides additional evi...
New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)
In a preclinical chronic colitis model, Tvardi's oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and mo...
Tvardi Therapeutics assumed with a Buy at Lucid Capital
Lucid Capital assumed coverage of Tvardi Therapeutics (TVRD) with a Buy rating and price target of $14, up from $6. The company’s first-generation molecule, TTI-101, provided early validation of the…
Tvardi Therapeutics to Participate in Upcoming Investor Events
HOUSTON, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule the...
Tvardi Therapeutics reports Q2 EPS (69c), consensus (63c)
Imran Alibhai, Chief Executive Officer of Tvardi, stated, “Since our last quarterly report, we have made significant progress in the clinical development of our STAT3 inhibitors. Regarding our next-ge...
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
HOUSTON, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, s...
Tvardi plans 2027 ulcerative colitis trial for oral STAT3 inhibitor TTI-109
Tvardi Therapeutics (TVRD) announced that it has selected ulcerative colitis as the initial disease indication for its next generation STAT3 inhibitor, TTI-109. Tvardi plans to initiate a study of TTI...
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
STAT3 acts as a convergent node downstream of multiple signaling pathways implicated in ulcerative colitis (UC), integrating immune dysregulation, inflammation and tissue remodeling
Tvardi Therapeutics upgraded to Overweight at Piper after Phase 1 data
As previously reported, Piper Sandler analyst Yasmeen Rahimi upgraded Tvardi Therapeutics (TVRD) to Overweight from Neutral with a price target of $13, up from $3, after the company presented topline…
Tvardi Therapeutics upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Tvardi Therapeutics (TVRD) to Overweight from Neutral with a $13 price target
Why Is Penny Stock Tvardi Therapeutics (TVRD) Up Today?
Tvardi Therapeutics stock surged after positive clinical trial data triggered an analyst upgrade.
Tvardi Therapeutics upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics (TVRD) to Outperform from Market Perform with a $10 price target after Phase 1 data for TTI-109 showed evidence of placebo-like GI…
Tvardi Therapeutics announces positive Phase 1 results for TTI-109
Tvardi Therapeutics (TVRD) announced results from its Phase 1 study of TTI-109, its next-generation STAT3 inhibitor. The study confirmed that TTI-109, designed as a prodrug of TTI-101, rapidly convert...
Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) an...
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Tvardi Therapeutics (TVRD) with a Buy rating and $9 price target The firm views the company as an undervalued STAT3 play. Tvardi is a clinical-stage…
Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)
Imran Alibhai, Chief Executive Officer of Tvardi, stated, “We are approaching a key inflection point with topline data from our next-generation STAT3 inhibitor, TTI-109, expected in June. These result...
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatoce...
Tvardi Therapeutics files $200M mixed securities shelf
16:07 EDT Tvardi Therapeutics (TVRD) files $200M mixed securities shelf
Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Tvardi Therapeutics (TVRD) to Underweight from Equal Weight with a price target of $3, down from $4. The company’s funding overhang makes the story “incrementally more challenged” ...
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule th...
Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler
Piper Sandler lowered the firm’s price target on Tvardi Therapeutics (TVRD) to $3 from $4 and keeps a Neutral rating on the shares. At Q4/FY25 earnings, Tvardi reiterated TTI-109’s Phase…
Tvardi Therapeutics price target lowered to $4 from $5 at Barclays
Barclays lowered the firm’s price target on Tvardi Therapeutics (TVRD) to $4 from $5 and keeps an Equal Weight rating on the shares. The firm updated the company’s model post…
Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)
Cash, cash equivalents and short-term investments as of December 31, 2025, were $30.8M, as compared to $31.6M as of December 31, 2024. Tvardi anticipates that its current cash runway is…